ZIMMER BIOMET HOLDINGS, INC. (ZBH) Form 10-Q — May 1, 2026
Zimmer Biomet reported first-quarter net sales of $2.09 billion, a 9.3% increase year-over-year, driven by the Paragon 28 acquisition, favorable foreign currency exchange rates, and market growth. Net earnings rose 31% to $238.1 million, or $1.22 per diluted share, aided by a $30 million favorable adjustment related to probable U.S. tariff refunds and lower restructuring charges compared to the prior year. The company repurchased $250.1 million of common stock during the quarter and authorized a new $1.5 billion share repurchase program.
Key figures
- Eps
- 1.22
- Revenue
- 2086.7
- Guidance
- Net sales growth of 2.5% to 4.5% in 2026
- Net Income
- 238.1
- Total Debt
- 7471.0
- Revenue Yoy
- 9.3%
- Cash Position
- 424.2
- Operating Profit
- 373.2
- Share Repurchases
- 250.1
- Restructuring Charges
- 6.3
Price after filing
Close on the filing date to close N calendar days later (from $82.90). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.